Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

Prostate cancer is one of the most common cancers diagnosed in men. Although it is the second-leading cause of cancer-related deaths for men in the U.S., it is also highly treatable, especially when ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due to its slow growing nature and reduced symptoms. Increased risk factors ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Prostate cancer affects one in five Australian men, making it the most common cancer in the country. Now, researchers at the Garvan Institute of Medical Research have produced the world's most ...

It is easy to assume that the prostate is healthy when there is no usual discomfort during urination. However, prostate ...

UP Reports 2 Lakh Cases Annually ...

Researchers at Endeavor Health and GoPath Diagnostics have developed a new genetic test that can help predict which men with prostate ...

Prostate cancer often earns the label “silent killer” because it can develop and progress for years without producing noticeable symptoms. Understanding this timeline becomes crucial for men seeking ...

Key Stats for Johnson & Johnson StockPrice change for Johnson & Johnsonstock in the last 6 months: 16%$JNJ Stock Price as of Oct. 23: $26452-Week High: $281$JNJ Stock Price Target: $279__Now Live: ...